University of Missouri School of Medicine MU Health School of Medicine
News Divider

Safer Drug Combination Found for High-Risk Atrial Fibrillation

Newer blood thinner a better option for some patients

Patients with high-risk atrial fibrillation, or AFib, often require one drug to regulate heart rhythm and a second drug to thin their blood and reduce the risk of stroke. A recent study led by a University of Missouri School of Medicine cardiologist found that use of a newer blood thinner significantly decreased the risk of strokes for patients with AFib who require both types of medication.

Greg Flaker

Although the anticoagulant warfarin has been the standard of care since the 1940s, more recent advancements in blood-thinning medication led to the development of the drug apixaban. The 2011 ARISTOTLE trial, conducted internationally, found that patients with atrial fibrillation taking apixaban had fewer strokes than those taking warfarin.

Greg Flaker, MD, the Wes and Simone Sorenson Chair in Cardiovascular Research at the MU School of Medicine, directed a team of researchers who recently reviewed data from the ARISTOTLE trial.

Flaker’s study indicated that the rate of stroke or blood clot to the body was 39 percent lower in those patients taking the amiodrarone-apixiban drug combination, compared to taking the amiodarone-warfarin combination.

“Although warfarin works very well for most patients who take it, we know that it can be a difficult medication to regulate ― especially when combining it with another drug,” Flaker said. “About 30 percent of patients taking warfarin experience fluctuations in blood thickness, depending on how warfarin is metabolized by the individual. Interaction with another drug, such as amiodarone, also affects how warfarin is metabolized.”

“Amiodarone is a common and effective drug used to normalize irregular heart rhythm caused by atrial fibrillation,” Flaker said. “However, because clotting is a complication associated with the condition, an anticoagulant or blood thinner is frequently used to reduce that possibility. Warfarin has been used as a blood thinner in this capacity for quite some time.”

Flaker, a member of the Steering Committee for the earlier ARISTOTLE clinical trial, and his research team reviewed data from that trial in their study.

“Our study mirrored the ARISTOTLE trial in that apixaban proved to be a better blood -thinning medication for all patients with atrial fibrillation,” Flaker said. “We looked at the specific drug combination of apixaban and amiodarone. We found that if you had atrial fibrillation and were taking amiodarone to control your heart rhythm, your stroke risk would be higher if you took warfarin than if you took apixaban.”

“Certainly there are factors such as cost, physician preference and patient decision-making that affect what drug we use to reduce stroke risks,” Flaker said. “The good news for AFib patients is that there is a very good alternative to warfarin for their physicians to consider when developing care strategies for patients with high-risk atrial fibrillation.”

The study led by Flaker recently was published in the Journal of the American College of Cardiology, a publication of the American College of Cardiology Foundation. Funding for the study was sponsored by Bristol-Myers Squibb and Pfizer.

Click here to download a high-resolution photo of Greg Flaker, MD.

Posted March 5, 2015

MU Health Magazine


News and Events

David Chang Grill with Caution
Wire bristles from barbecue brushes can cause serious injuries
Tahir Rahman Extreme Beliefs Often Mistaken for Insanity, New Study Finds
Researchers say new term offers more precise definition of non-psychotic behaviors
Paul Tatum Family Medicine Professor Wins Distinguished Physician Award
Tatum recognized for outstanding care of patients near the end of life
Seth Sherman Minimally Invasive Tendon Repair Technique Supports Knee Movement Sooner after Surgery
Researchers found suture anchors, a less-invasive repair technique, responded better to strength-testing after surgery
2016 Graduation MU School of Medicine Awards 86 Medical Degrees at Commencement Ceremony
The graduates will go on to receive additional training as resident physicians in their chosen specialties
Patrice Delafontaine MU School of Medicine Dean Inducted into Prestigious Medical Society
Delafontaine joins elite group of physicians in American Clinical and Climatological Association
Steven Zweig MU Family Medicine Ranked Among Nation’s Best by U.S. News & World Report
Department has been in top 10 for 23 consecutive years
Uzma Khan MU Initiative Helps Rural Doctors Treat Chronic Pain
Show-Me ECHO to offer special training session April 28
Legacy Teachers MU School of Medicine Program Expands to Other Medical Schools
MU’s Legacy Teachers program lets students recognize patients as educators
Susan Nagel Oil and Gas Wastewater Disposal May Increase Endocrine Disrupting Activity
Scientists draw conclusions after study at natural gas and oil extraction wastewater disposal facility
St. Baldricks 2016 Participants Go Bald for Childhood Cancer Research
Community donates more than $40,000 to the cause

Media Relations
University of Missouri Health System
One Hospital Drive, DC028.00
Columbia, MO 65212
24/7 on-call pager: (573) 876-0708

Mary Jenkins
(573) 882-7299

Jeff Hoelscher
(573) 884-1608

Derek Thompson
(573) 882-3323

Diamond Dixon
(573) 884-7541

Justin Kelley (Photographer)
(573) 882-5786
Pager (573) 397-9289

Web Communications
University of Missouri Health System
One Hospital Drive, MA204G, DC018.00
Columbia, MO 65212
(573) 884-0298

Jennifer Orford
(573) 882-0298

Deidra Ashley
(573) 884-3988

Jesslyn Chew
(573) 884-2891

Velvet Hasner
(573) 884-1115

Justin Willett
(573) 884-7740

Printer Friendly
Follow us on Twitter!   Facebook   YouTube Videos   Instagram   Pinterest  
Website created and maintained by the Office of Communications. Contact the MU School of Medicine.
Revised: March 26, 2015 - Copyright © 2014 - Curators of the University of Missouri. All rights reserved. DMCA and other copyright information. An equal opportunity/access/affirmative action/pro-disabled and veteran employer.